Table-II.
NVD, NVE, and BCVA status at presentation and follow up (n=76).
| PRP-Group n=38 (Mean±SD) | PRP Plus-IVB Group n=38 (Mean±SD) | P | |
|---|---|---|---|
| NVD (DD%±SD) | |||
| Baseline | 40±5 | 40±7 | - |
| 4 weeks | 50±7 | 10±5 | 0.00004 |
| 3 Months | 40±6 | 11±3 | 0.00008 |
| 6 Months | 40±4 | 12±2 | 0.00004 |
| NVE (DD±SD) | |||
| Baseline | 2±0.75 | 2±0.50 | - |
| 4 weeks | 2.25±0.75 | 01±0.5 | 0.0001 |
| 3 Months | 2.00±0.50 | 0.75±0.25 | 0.0001 |
| 6 Months | 2.10±0.60 | 0.70±0.35 | 0.0001 |
| CVA (log MAR) | |||
| Baseline | 0.30±0.07 | 0.30±0.05 | - |
| 4 weeks | 0.40±0.05 | 0.1±0.03 | 0.00004 |
| 3 Months | 0.40±0.04 | 0.1±0.02 | 0.00002 |
| 6 Months | 0.42±0.07 | 0.1±0.04 | 0.00002 |
| CMT | |||
| Baseline | 250.5±10.3 | 253.91±15.2 | 0.393032 |
| 4 weeks | 273.06±11.5 | 236.95±17.3 | 0.001116 |
| 3 Months | 267±10.6 | 235.16±14.9 | 0.004973 |
| 6 Months | 299±9.7 | 240.53±14.1 | 0.000011 |
PRP: panretinal photocoagulation, PRP-plus: panretinal photocoagulation plus intravitreal injection of 1.25 mg of bevacizumab, NVD: Neovessels on the disc, NVE: new vessels elsewhere, DD: Disc diameter, CVA: corrected visual acuity, logMAR: logarithm of minimum angle of resolution.